Nicotine Transdermal System Patch 14 mg
Aveva is recalling 14 mg Nicotine Transdermal System Patches due to elevated levels of oxidative-related impurities.
Stop using the affected patches and contact your healthcare provider or pharmacist for guidance on an alternative smoking cessation product.
Why it was recalled
Aveva is recalling Nicotine Transdermal System Patches due to elevated levels of oxidative-related impurities found during stability testing. These impurities exceed shelf-life specifications for the affected product.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, Distributed by: RUGBY LABORATORIES, Indianapolis, IN 46268, www.majorpharmaceuticals.com, NDC 0536-5895-88.
- Recall #
- D-0550-2026
Where it was sold
Distributed nationwide.
Official source
Editorial summary by Recall Canary · last updated 2026-05-27 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification